149 related articles for article (PubMed ID: 8861661)
21. Induction of CYP2D6 in pregnancy.
Wadelius M; Darj E; Frenne G; Rane A
Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
[TBL] [Abstract][Full Text] [Related]
22. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
23. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.
Lutz U; Völkel W; Lutz RW; Lutz WK
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):217-25. PubMed ID: 15556536
[TBL] [Abstract][Full Text] [Related]
24. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection.
Lam YW; Rodriguez SY
Ther Drug Monit; 1993 Aug; 15(4):300-4. PubMed ID: 8236365
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of dextromethorphan N-demethylation activity as a biomarker for cytochrome P450 3A activity in man.
Kawashima Y; Hagiwara M; Inoue Y; Someya T
Pharmacol Toxicol; 2002 Feb; 90(2):82-8. PubMed ID: 12071430
[TBL] [Abstract][Full Text] [Related]
26. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes.
Kerry NL; Somogyi AA; Mikus G; Bochner F
Biochem Pharmacol; 1993 Feb; 45(4):833-9. PubMed ID: 8452558
[TBL] [Abstract][Full Text] [Related]
27. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
[TBL] [Abstract][Full Text] [Related]
28. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
[TBL] [Abstract][Full Text] [Related]
29. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
Tracy TS; Venkataramanan R; Glover DD; Caritis SN;
Am J Obstet Gynecol; 2005 Feb; 192(2):633-9. PubMed ID: 15696014
[TBL] [Abstract][Full Text] [Related]
30. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
31. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
32. CYP2D6 phenotyping with dextromethorphan.
Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients.
Daali Y; Cherkaoui S; Doffey-Lazeyras F; Dayer P; Desmeules JA
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):56-63. PubMed ID: 18065299
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.
Wieling J; Tamminga WJ; Sakiman EP; Oosterhuis B; Wemer J; Jonkman JH
Ther Drug Monit; 2000 Aug; 22(4):486-96. PubMed ID: 10942192
[TBL] [Abstract][Full Text] [Related]
35. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats.
Zhang S; Song N; Li Q; Fan H; Liu C
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):78-89. PubMed ID: 18614408
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC; Nation RL; Somogyi AA
Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
[TBL] [Abstract][Full Text] [Related]
37. Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity.
Amaeze OU; Czuba LC; Yadav AS; Fay EE; LaFrance J; Shum S; Moreni SL; Mao J; Huang W; Isoherranen N; Hebert MF
J Clin Pharmacol; 2023 Mar; 63(3):363-372. PubMed ID: 36309846
[TBL] [Abstract][Full Text] [Related]
38. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
39. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
40. Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients.
Antunes MV; Staudt DE; Raymundo S; de Oliveira V; Gössling G; Pirolli R; Biazús JV; Cavalheiro JA; Rosa DD; Schwartsmann G; Linden R
Clin Biochem; 2014 Aug; 47(12):1084-90. PubMed ID: 24747158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]